DRTS · Alpha Tau Medical Ltd. · Stock research

Current Thesis

The character of this tape flipped from the June catalyst-gap drift back to an accelerating breakout. On 2026-06-23 Alpha Tau treated its first glioblastoma patient outside the US at Hadassah (Jerusalem) using a proprietary brain applicator and stereotactic navigation; the print carried the stock +17.9% (Simply Wall St, 2026-07-06) and pushed it to a fresh 52-week high of $14.11. At the 2026-07-11 close of $12.56 (day range $12.01–$13.40) the name has reclaimed the $11.62 prior high and the $11.99 Tolmar equity strike, converting the overhead supply the June dossier flagged into support. The setup is now a dated binary: on 2026-07-21 the company gives a podium presentation at AHNS in Boston with complete top-line data from the Alpha DaRT + pembrolizumab combination in elderly head-and-neck cancer. That readout, nine sessions out, either extends the breakout leg or breaks it.

Bullish and bearish views on Alpha Tau Medical Ltd.

The model's bull view on Alpha Tau Medical Ltd. (DRTS), in brief: The undated summer H&N data now has a hard date. The bear view: Insiders are selling into the rip. CFO Raphi Levy sold 2,127 shares (~$27.7k) on 2026-07-02 and 2,270 shares (~$31.8k) on 2026-07-07 small and likely programmatic, but distribution while the stock made new highs, not accumulation. The 2026-07-21 readout is a genuine coin-flip.… Both cases follow in full.

Bull Case

• The undated summer H&N data now has a hard date. Abstract accepted 2026-05-05 for a podium slot at the AHNS 12th International Conference on Head and Neck Cancer, Proffered Papers session 2026-07-21, 10:30am–12:00pm ET. Complete top-line from Alpha DaRT + pembrolizumab in locally-advanced/metastatic HNSCC. This is the specific catalyst the prior read could only gesture at.
• Breakout confirmed by price, not just news. The 2026-06-23 GBM treatment drove a +17.9% move and a new 52-week high ($14.11 vs the June $11.62), reclaiming the Tolmar equity strike ($11.99). Good news is moving the stock again after the June clearance failed to.
• Commercial validation still anchors the story. Tolmar US prostate deal (2026-06-03): $35M upfront ($20M equity priced at $11.99), up to $161.5M prostate milestones, 20-year US exclusivity, Tolmar funding 60% of net-sales supply cost, plus a bladder option. A partner paid a premium for equity now sitting below the tape.
• ASCO pancreatic survival remains the credibility datapoint. Pooled Phase I/II EUS-guided data (2026-06-01): median OS up to 17.1 months in heavily pretreated PDAC, Grade ≥3 AEs only 9%, no treatment-related deaths, against historical 4–7 months.
• Runway removes the financing overhang. $80.2M cash at Q1 (2026-05-18) plus ~$35M Tolmar inflow ≈ $115M pro forma against ~$22–25M/quarter burn a stated 2–3 year runway past the near-term readouts.
• Analyst/consensus sits above the tape. Community/consensus fair value near $14.20, with prior sell-side marks clustered $14–$17 (Ladenburg $14, HC Wainwright $15, Barclays Overweight $17) roughly 13% above the 2026-07-11 close.

Bear Case

• Insiders are selling into the rip. CFO Raphi Levy sold 2,127 shares (~$27.7k) on 2026-07-02 and 2,270 shares (~$31.8k) on 2026-07-07 small and likely programmatic, but distribution while the stock made new highs, not accumulation.
• The 2026-07-21 readout is a genuine coin-flip. Small-n, elderly HNSCC combination top-line can gap the stock down on a soft OS/response signal or any safety flag. Buying at $12.56, ~28% off the June lows, is paying up into that binary.
• Still pre-revenue. Q1 net loss $22.9M, EPS -$0.26 vs -$0.12 consensus (2026-05-18); annualized losses running ~$56.9M. Valuation is entirely catalyst-and-narrative supported.
• Thin, gap-prone float. Low ADV (~1M shares) small-cap Israeli ADR near $1.1B cap. The +17.9% one-day move shows the reflexivity, and it cuts both ways on a single headline.
• The larger value binary is still months out and undated. The ReSTART cSCC pivotal top-line (Breakthrough Device, 88 patients enrolled 2026-05-08, first PMA module 2026-01-05) is guided to late H2 / ~year-end 2026 nothing precise inside the next quarter after 2026-07-21.

Setup & Price Structure

• Last print $12.56 (2026-07-11), intraday $12.01–$13.40; 52-week range $2.87–$14.11.
• The reclaim of the $11.62 prior high and $11.99 Tolmar strike turned prior overhead supply into a support shelf; the June breakout base sat near ~$8.95.
• The move to a new 52-week high on the 2026-06-23 GBM catalyst is a clean higher-high, not a mean-reversion bounce.
• Extension is moderate: the stock is near highs but not stretched into a blowoff far above its moving averages; overhead resistance is the $14.11 high and the ~$14.20 consensus zone.
• Expect gap risk into and out of the 2026-07-21 AHNS session given the thin ADV.

Catalyst Calendar (next 30 days)

• 2026-07-21 AHNS 12th International Conference on Head and Neck Cancer, Boston (conference runs 2026-07-18 to 07-22). Podium, Radiation and Adjuvant Therapies session, 10:30am–12:00pm ET: complete top-line Alpha DaRT + pembrolizumab HNSCC data. Hard, dated binary.
• ~2026-08-10 (est.) Q2 earnings; just outside the 30-day window, no blackout inside it.
• Late H2 / ~year-end 2026 (undated) ReSTART cSCC pivotal top-line, the larger value catalyst.

Elapsed catalysts

• Ongoing further feasibility/procedure updates possible but undated (first ex-US GBM treatment 2026-06-23). _(passed 26d ago)_

What Would Change Our Mind

• A daily close below $11.60 relinquishes the reclaimed breakout shelf (the prior 52-week high and the $11.99 Tolmar equity strike) and points price back toward the ~$8.95 pre-deal base.
• A soft or negative 2026-07-21 AHNS HNSCC top-line read (weak OS, low response rate, or a safety signal) breaks the acceleration thesis regardless of price.
• A ReSTART cSCC PMA deficiency letter or a REGAIN safety reversal removes the multi-shot optionality.
• Insider selling scaling well beyond the small July amounts, or the theme going fully mainstream (peak retail, broad sell-side pile-in) with no fresh undiscounted catalyst.

Correlation Notes

• Idiosyncratic small-cap clinical radiation-oncology; on catalyst days it decouples from SPY and even from XBI, though broad biotech risk appetite sets the backdrop for how any readout is received.
• Israeli ADR carries geopolitical headline sensitivity independent of the clinical story.
• No direct listed peer for the Alpha DaRT alpha-emitter platform; the private Tolmar partnership is the only commercial counterparty. Read radiopharmaceutical/radioligand sentiment as the nearest theme proxy for flow.
• Thin ADV means single-headline gaps dominate; correlation to any index is low precisely on the days that matter. Current_conviction: MEDIUM the re-acceleration and shelf reclaim are real, but a fresh entry at $12.56 is paying up into a binary head-and-neck readout with no peer-cluster confirmation and small insider selling into the move. Archetype: Binary Catalyst (the 2026-07-21 AHNS clinical top-line is the near-term driver).

themes: precision-biotech-therapeutics, oncology-immunology.